vaccine pipeline

A new era of MAPS vaccines combating the most challenging and resistant diseases.

Affinivax tailors the design of each of its MAPS vaccine candidates to optimize the protective immune response desired from the polysaccharide and/or protein antigens. We believe MAPS represents a significant step forward to help address major healthcare challenges posed by novel and resistant bacterial infections, and also actively exploring programs targeting viral infections and oncology.

Affinivax pipeline

 

Addressing diseases for global impact.

 

AFX3772: Lead MAPS vaccine program for Streptococcus pneumoniae

Affinivax’s lead vaccine candidate, AFX3772, is a Streptococcus pneumoniae vaccine that includes 24 pneumococcal polysaccharides, more than any other vaccine on the market, as well as two conserved pneumococcal proteins. LEARN MORE

MAPS vaccine program for healthcare-associated infections

Disease Challenge:
Healthcare-associated infections (HAIs) have now emerged as a significant global health concern due to the significant increase in antimicrobial resistance. The Centers for Disease Control and Prevention estimates that 4% of patients in the U.S. alone will contract an HAI each year in medical facilities including ambulatory surgical centers, hospice centers, nursing homes and rehabilitation centers. HAIs can significantly delay patient recovery and increase healthcare costs, with the direct costs to medical facilities estimated at between $28 and $45 billion1. Of the approximately two million patients who acquire a HAI annually in the U.S. alone, an estimated 90,000 will die1. The most common bacterial pathogens causing HAIs in U.S. medical facilities include Clostridium difficile, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Escherichia coli,2 many of which are highly resistant to available antibiotic therapies. Current therapeutic options against HAIs are limited and there are no vaccines available today to address this expanding global health crisis.

MAPS Solution:
Addressing antimicrobial resistance head-on, Affinivax is advancing several first-in-class MAPS vaccines targeting Klebsiella pneumoniae and Pseudomonas aeruginosa, Clostridium difficile, and Staphylococcus aureus.

 

Additional MAPS vaccine programs

Disease Challenge:
Infectious diseases cause deaths of over 17 million people a year worldwide and at least 30 new diseases have emerged in the last 20 years, which threatens the health of hundreds of millions of people3, most recently the COVID-19 pandemic. In addition to bacterial infections and viral infections, there are also opportunities for cancer vaccines as areas to apply innovative vaccine technologies.

MAPS Solution:
Applicability of the MAPS technology has been demonstrated for additional bacterial pathogens which have a significant impact on healthcare in the developing world. Affinivax will explore initiation of these important additional MAPS vaccine programs in collaboration with global health and government partners.

While the company’s initial focus has been on bacterial infections, it is now also advancing discovery efforts to develop preventive and therapeutic vaccines in other therapeutic areas, including viruses and cancer immunology. We believe that our novel MAPS platform technology offers a significant step forward to combat these infections, with the potential to make a meaningful impact on global public health.

 

1 Patricia W Stone (2014) “Economic burden of healthcare-associated infections: an American perspective,” Expert Review of Pharmacoeconomics & Outcomes Research, 9:5, 417-422, DOI: 10.1586/erp.09.53. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2827870/.

2 Multistate Point-Prevalence Survey of Health Care–Associated Infections. Shelley S. Magill, M.D., Ph.D., Jonathan R. Edwards, M.Stat., Wendy Bamberg, M.D., Zintars G. Beldavs, M.S., Ghinwa Dumyati, M.D., Marion A. Kainer, M.B., B.S., M.P.H., Ruth Lynfield, M.D., Meghan Maloney, M.P.H., Laura McAllister-Hollod, M.P.H., Joelle Nadle, M.P.H., Susan M. Ray, M.D., Deborah L. Thompson, M.D., M.S.P.H., Lucy E. Wilson, M.D., and Scott K. Fridkin, M.D. for the Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. N Engl J Med 2014; 370:1198-1208, March 27, 2014.

3 https://www.who.int/whr/1996/media_centre/press_release/en/

Trade marks are owned by or licensed to the GSK group of companies.
©2022 GSK group of companies or its licensor.

Back to Top
 

This links to an external website.

Continue